Pneumonia Clinical Trial
Official title:
A Phase IV Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs.Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)
Verified date | April 5, 2017 |
Source | National Institute of Allergy and Infectious Diseases (NIAID) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multi-center, randomized, double-blind, placebo-controlled, superiority clinical trial will test the effectiveness of short (5-day) vs.standard (10-day) course therapy in children who are diagnosed with CAP and initially treated in outpatient clinics, urgent care facilities, and emergency departments. Primary objective is to compare the composite overall outcome (Desirability of Outcome Ranking, DOOR) among children 6-71 months of age with CAP assigned to a strategy of short course (5 days) vs standard course (10 days) outpatient beta-lactam therapy at Outcome Assessment Visit #1 (Study Day 8 +/- 2 days)
Status | Completed |
Enrollment | 385 |
Est. completion date | December 16, 2019 |
Est. primary completion date | December 16, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 71 Months |
Eligibility | Inclusion Criteria: 1. Age 6 - 71 months 2. Provider diagnosis of CAP and prescription of antibiotic therapy with amoxicillin, amoxicillin-clavulanate, or cefdinir - amoxicillin or amoxicillin-clavulanate prescribed at a amoxicillin dose of 60 mg/kg/day -- cefdinir prescribed at a minimum dose of 10 mg/kg/day 3. Parental report of clinical improvement - based on lack of either subjective or known fever temperature >/= 38.3°C in the preceding 24 hours; current respiratory rate no greater than 50 breaths/minute (<2 years of age) or breaths/minute (= / > 2 years of age); and current grade of cough < 3 4. Ability of a parent or guardian to understand and comply with the study procedures and be available for all study visits 5. Signed written informed consent by a parent or guardian Exclusion Criteria: 1. Treatment with any systemic antibiotic therapy within 7 days before the diagnosis of CAP 2. Initial therapy for CAP with combination antibiotic therapy - amoxicillin, amoxicillin/clavulanate or cefdinir plus one or more additional oral, intravenous, or intramuscular antibiotics 3. History of anaphylaxis or severe drug allergy to amoxicillin, if prescribed amoxicillin or amoxicillin/clavulanic acid; or oral cephalosporin antibiotics (except cefaclor), if prescribed cefdinir 4. Presence of concomitant bacterial infection that requires > 5 days of antibiotic therapy 5. Radiographic findings (where applicable) of complicated pneumonia at presentation or any subsequent chest radiograph up to the time of enrollment - clinically significant pleural effusion, lung abscess, or pneumatocele 6. Hospitalization for pneumonia during Day -5 to -1 of antibiotic therapy for CAP - subjects who require serial clinical assessments, but are discharged within 24 hours will not be considered hospitalized and will not satisfy this exclusion criterion 7. Pneumonia due to S. aureus or group A streptococcus documented by positive blood culture or PCR, at the time of enrollment 8. History of pneumonia within the previous 6 months 9. History of persistent asthma within the previous 6 months or current acute asthma exacerbation - persistent asthma is defined as receiving daily asthma maintenance therapy such as inhaled corticosteroids, cromolyn, theophylline, or leukotriene receptor antagonists -- acute asthma exacerbation is defined as receiving concomitant bronchodilator therapy and systemic corticosteroids 10. Provider-diagnosis of aspiration pneumonia, bronchiolitis, or bronchitis 11. Surgery or other invasive procedures of the upper or lower airway (e.g., bronchoscopy, laryngoscopy) with general anesthesia or hospitalization </=7 days before diagnosis of CAP 12. History of an underlying chronic medical condition - including chronic heart disease, chronic lung disease (except asthma), congenital anomalies of the airways or lung, cystic fibrosis, chronic renal disease including nephrotic syndrome, protein-losing enteropathy of any cause, severe malnutrition, neurocognitive disorders, metabolic disorders (including phenylketonuria), or genetic disorders (note: genetic syndromes such as Down syndrome and Edwards Syndrome are excluded; however, children with genetic disorders (e.g., hemophilia) but who do not have a genetic syndrome may not satisfy this particular exclusion criterion; it is important that children with such genetic disorders do not have symptoms and/or comorbidities that would pose additional risk to them nor jeopardize the adequacy of study assessments.) 13. History of a condition that compromises the immune system - HIV infection, primary immunodeficiency, anatomic or functional asplenia; receipt of a hematopoietic stem cell or solid organ transplant at any time; receipt of immunosuppressive therapy including chemotherapeutic agents, biologic agents, antimetabolites or radiation therapy during the past 12 months; or daily use of systemic corticosteroids for more than 7 consecutive days during the past 14 days 14. Any other condition that in the judgment of the investigator precludes participation because it could affect the safety of the subject 15. Current enrollment in another clinical trial of an investigational agent 16. Previous enrollment in this trial |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama - Children's of Alabama - Infectious Diseases/Virology | Birmingham | Alabama |
United States | Cincinnati Children's Hospital Medical Center - Infectious Diseases | Cincinnati | Ohio |
United States | Duke Human Vaccine Institute - Duke Vaccine and Trials Unit | Durham | North Carolina |
United States | Arkansas Children's Hospital - Infectious Diseases | Little Rock | Arkansas |
United States | University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases | Louisville | Kentucky |
United States | Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center | Nashville | Tennessee |
United States | Children's Hospital of Philadelphia - The Center for Pediatric Clinical Effectiveness | Philadelphia | Pennsylvania |
United States | Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric | Pittsburgh | Pennsylvania |
United States | Washington University School of Medicine in St. Louis - Infectious Diseases | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Desirability of Outcome Ranking (DOOR) | DOOR is a composite endpoint created using clinical outcomes from the first 5 days and at Outcome Assessment Visit #1 (OAV #1). It is based on adequate clinical response at OAV #1, solicited symptoms from first 5 days and number of days of antibiotics use for worsening pneumonia from the first 5 days of the study. | Outcome Assessment Visit 1 (Study Day 8 +/- 2 days) | |
Secondary | Desirability of Outcome Ranking (DOOR) | DOOR is a composite endpoint created using clinical outcomes from the first 18 days and at Outcome Assessment Visit #2 (OAV #2). It is based on adequate clinical response at OAV #2, solicited symptoms from first 18 days and number of days of antibiotics use for worsening pneumonia from the first 18 days of the study. | Outcome Assessment Visit 2 (Study Day 22 +/- 3 days) | |
Secondary | Resolution of Symptoms (a Component of DOOR) | This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #1. | Outcome Assessment Visit 1 (Study Day 8 +/- 2 days) | |
Secondary | Resolution of Symptoms (a Component of DOOR) | This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #2. | Outcome Assessment Visit 2 (Study Day 22 +/- 3 days) | |
Secondary | Adequate Clinical Response Rates (a Component of DOOR) | Lack of adequate clinical response at OAV #1 is defined as the presence of a medically attended visit to an Emergency Department (ED) or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 5. | Outcome Assessment Visit 1 (Study Day 8 +/- 2 days) | |
Secondary | Adequate Clinical Response Rates (a Component of DOOR) | Lack of adequate clinical response at OAV #2 is defined as the presence of a medically attended visit to an ED or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 18. | Outcome Assessment Visit 2 (Study Day 22 +/- 3 days) | |
Secondary | Number of Participants Reporting Solicited Symptoms | This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 5 | Outcome Assessment Visit 1 (Study Day 8 +/- 2 days) | |
Secondary | Number of Participants Reporting Solicited Symptoms | This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 18 | Outcome Assessment Visit 2 (Study Day 22 +/- 3 days) | |
Secondary | Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits | This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 5 | Outcome Assessment Visit 1 (Study Day 8 +/- 2 days) | |
Secondary | Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits | This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 18 | Outcome Assessment Visit 2 (Study Day 22 +/- 3 days) | |
Secondary | Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits | This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 5 | Outcome Assessment Visit 1 (Study Day 8 +/- 2 days) | |
Secondary | Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits | This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 18 | Outcome Assessment Visit 2 (Study Day 22 +/- 3 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Completed |
NCT05815264 -
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
|
Phase 1 | |
Recruiting |
NCT04589936 -
Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care
|
N/A | |
Completed |
NCT02905383 -
The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital
|
N/A | |
Terminated |
NCT03944551 -
Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa
|
N/A | |
Completed |
NCT06210737 -
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years
|
Phase 4 | |
Terminated |
NCT04660084 -
Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Not yet recruiting |
NCT04171674 -
Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.
|
N/A | |
Active, not recruiting |
NCT03140163 -
Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR]
|
N/A | |
Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Recruiting |
NCT02515565 -
Physiotherapy in Patients Hospitalized Due to Pneumonia.
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01446926 -
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
|
Phase 1 | |
Completed |
NCT01399723 -
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
|
Phase 3 | |
Completed |
NCT01416519 -
Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01416506 -
Community-Acquired Pneumonia (CAP) Surveillance
|
N/A | |
Terminated |
NCT02358642 -
Drug to Prevent Pneumonia in the Tube Fed
|
Phase 4 |